A potently neutralizing SARS-CoV-2 antibody inhibits variants of concern by utilizing unique binding residues in a highly conserved epitope

With the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants with increased transmissibility and potential resistance, antibodies and vaccines with broadly inhibitory activity are needed. Here, we developed a panel of neutralizing anti-SARS-CoV-2 monoclonal antibodies...

Descripción completa

Detalles Bibliográficos
Autores principales: VanBlargan, Laura A., Adams, Lucas J., Liu, Zhuoming, Chen, Rita E., Gilchuk, Pavlo, Raju, Saravanan, Smith, Brittany K., Zhao, Haiyan, Case, James Brett, Winkler, Emma S., Whitener, Bradley M., Droit, Lindsay, Aziati, Ishmael D., Bricker, Traci L., Joshi, Astha, Shi, Pei-Yong, Creanga, Adrian, Pegu, Amarendra, Handley, Scott A., Wang, David, Boon, Adrianus C.M., Crowe, James E., Whelan, Sean P.J., Fremont, Daved H., Diamond, Michael S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Inc. 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373659/
https://www.ncbi.nlm.nih.gov/pubmed/34481543
http://dx.doi.org/10.1016/j.immuni.2021.08.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8373659/
https://www.ncbi.nlm.nih.gov/pubmed/34481543
http://dx.doi.org/10.1016/j.immuni.2021.08.016

Ejemplares similares